These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Delayed fingolimod-associated asystole. Espinosa PS; Berger JR Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609 [TBL] [Abstract][Full Text] [Related]
7. Cystoid macular edema associated with fingolimod use for multiple sclerosis. Afshar AR; Fernandes JK; Patel RD; Ksiazek SM; Sheth VS; Reder AT; Hariprasad SM JAMA Ophthalmol; 2013 Jan; 131(1):103-7. PubMed ID: 23307220 [No Abstract] [Full Text] [Related]
8. Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Lysandropoulos AP; Benghiat F Mult Scler; 2013 Oct; 19(11):1551-2. PubMed ID: 23817558 [No Abstract] [Full Text] [Related]
9. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Gross CM; Baumgartner A; Rauer S; Stich O Neurology; 2012 Nov; 79(19):2006-7. PubMed ID: 23035074 [No Abstract] [Full Text] [Related]
10. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod]. Komoly S Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178 [No Abstract] [Full Text] [Related]
11. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Rolf L; Muris AH; Damoiseaux J; van Daele M; Hupperts R Neurology; 2014 Mar; 82(11):1008-9. PubMed ID: 24523479 [No Abstract] [Full Text] [Related]
12. Prolonged and symptomatic bradycardia following a single dose of fingolimod. Faber H; Fischer HJ; Weber F Mult Scler; 2013 Jan; 19(1):126-8. PubMed ID: 22729989 [TBL] [Abstract][Full Text] [Related]
13. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)]. Popova NF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166 [No Abstract] [Full Text] [Related]